COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
Study Details
Study Description
Brief Summary
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
To determine if Fisetin treatment can prevent deterioration of oxygenation status as measured by S/F ratio: SpO2/ FiO2, as well as prevent deterioration in physical function (frailty) and hyper-inflammation, other measures of oxygenation status (progression to supplemental oxygen requirement, assisted breathing/ ventilation), and progression from mild/ moderate to severe/ critical proven SARS-CoV-2 infection in hospitalized patients and to evaluate the safety and tolerability of Fisetin in this patient population.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment Group Subjects will receive treatment drug Fisetin |
Drug: Fisetin
~20 mg/kg/day oral, NG or D tube course for 2 consecutive days
Other Names:
|
| Placebo Comparator: Placebo Group Subjects will receive placebo |
Drug: Placebo
Placebo looks exactly like the study drug, but it contains no active ingredient.
|
Outcome Measures
Primary Outcome Measures
- Serious Adverse Events [6 months]
Number of participants to experience serious adverse events and hypersensitivity reactions.
- Change in oxygenation status [baseline, Day 3, 7, 10, 14, 17 and 30; Months 3 and 6]
change in oxygenation levels as measured by S/F ratio (SPO2/FiO2)
Secondary Outcome Measures
- CoV Severity Category [6 months]
Number of participants to progress to severe or critical classification CoV
Eligibility Criteria
Criteria
Inclusion Criteria - Patients must meet all of the following inclusion criteria to be enrolled in this study.
- Men or women 60 years of age or older
OR
Age 18 - 59 years WITH at least one of the following comorbidities:
-
BMI greater than or equal to 35
-
Diabetes
-
Asthma/ Chronic Obstructive Pulmonary Disease (COPD)
-
Previous Myocardial Infarction
-
Previous Stroke/ Cerebrovascular Accident (CVA)
-
Hypertension/ Atherosclerosis/ Peripheral Vascular Disease
-
Smoking and/or vaping
-
Other conditions associated with senescent cell accumulation (i.e. previous chemotherapy or radiation)
-
SpO2 greater than or equal to 85% (on room air or less than or equal to 2 L of supplemental oxygen)
-
Willing and able to provide written informed consent or have a legally authorized representative (LAR) who will provide informed consent
-
SARS-CoV-2 infection confirmed by PCR test at Mayo Clinic (or other CLIA certified) laboratory within 10 days prior to randomization.
Exclusion Criteria - Patients who meet any of the following exclusion criteria are not to be enrolled in this study.
General Exclusion Criteria
-
Presence of any condition that the Investigator or the subject's attending physician believes would put the subject at risk or would preclude the patient from successfully completing the trial
-
Pregnant and/or lactating. Women of childbearing potential (WCBP) must have a negative pregnancy test within 72 hours prior to randomization
-
WCBP who are unwilling to abstain from sex or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration
-
Men who are unwilling to abstain from sex with WCBP or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration
Laboratory Exclusion Criteria
-
Total bilirubin >3X upper limit of normal or as per clinical judgment.
-
Serum aspartate transaminase (AST) or alanine aminotransferase (ALT) >4x the upper limits of normal or as per clinical judgment.
-
Hemoglobin <7 g/dL; white blood cell count ≤ 2,000/mm3 (< or = 2.0 x 109/L) or > or = 20,000/mm3 (> or = 20 x 109/L); platelet count < or = 40,000/µL (< or = 40 x 109/L); absolute neutrophil count < or = 1 x 109/L; lymphocyte count <0.3 x 109/L at screening or as per clinical judgment.
-
Unstable (as per clinical judgment) major cardiovascular, renal, endocrine, immunological, or hepatic disorder.
-
eGFR <25 ml/ min/ 1.73 m2 or as per clinical judgment.
-
Plasma and/or serum glucose >300 or as per clinical judgment.
Clinical History Exclusion Criteria
-
Human immunodeficiency virus infection.
-
Known active hepatitis B or C infection.
-
Invasive fungal infection.
-
Uncontrolled (as per clinical judgement) pleural/pericardial effusions or ascites.
-
New/active invasive cancer except non-melanoma skin cancers.
Medication Exclusion Criteria (See Appendices 1-3 for additional information)
-
Known hypersensitivity or allergy to Fisetin.
-
Patients currently using medications which utilize CYP450 2C9 for metabolism. These medications include: Fosphenytoin, Phenytoin, Warfarin, Glimepiride, Diclofenac, Bosentan, and Glyburide. Patients taking any of these medications may participate if the medications can be held immediately before the 1st IP administration until at least 10 hours after the last (2nd) IP administration and the patient is otherwise eligible.
-
Patients currently using medications which utilize CYP2C9, CYP2C19, CYP1A2, OATP1B1. These medications include: Olanzapine, Clozapine, Theophylline, Tizanidine, Warfarin, Rameltoen, Tacrine, Duloxetine, Mexiletine, Riluzole, and Atomoxetine. Patients taking any of these medications may participate if the medications can be held immediately before the 1st IP administration until at least 10 hours after the last (2nd) IP administration and the patient is otherwise eligible.
-
Patients currently using medications which are strong inhibitors of CYP3A4. These medications include: Atazanavir, Ceritinib, Clarithromycin, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mefipristone, Nefazodone, Nelfinavir, Ombitasivir-paritaprevir-ritonivir, Ombitasivir-paritaprevir-ritonivir-plus dasabuvir, Posaconazole, Saquinavir, Telithromycin, Tucatinib, and Voriconazole. Patients taking any of these medications may participate if the medications can be held immediately before the 1st IP administration until at least 10 hours after the last (2nd) IP administration and the patient is otherwise eligible.
-
Patients currently using antifungals. If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are subtherapeutic or therapeutic.
-
Patients taking any of these medications may participate if the medications can be held immediately before the 1st IP administration until at least 10 hours after the last (2nd) IP administration and the patient is otherwise eligible:
-
Cardiac: digoxin, flecainide, amiodarone
-
Psychiatric: lithium, thioridazine
-
Neurologic: carbamazepine, phenobarbital
-
Antimicrobial/fungal: aminoglycosides (e.g. amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomysin, streptomycin, tobramycin), rifampin
-
Anticoagulants/ Antiplatelets: warfarin
-
Others: methotrexate, nitroglycerin, St. John's wort, tyrosine kinase inhibitors, tacrine, diclofenac
- Participation in other clinical trials involving treatment for SARS-CoV-2. (unless reviewed and approved by the Principal Investigator). Note that institutional standard of care treatment of SARS-CoV-2 including glucocorticoids, hydroxychloroquine, azithromycin, remdesivir, anti-spike antibodies, and/or convalescent plasma are not excluded from the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
Investigators
- Principal Investigator: James L Kirkland, MD, PhD, Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 20-003936